January 4, 2022

Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In vitro assays confirmed that increased resistance to lenacapavir was associated with decreased replication capacity of mutant viruses. In the clinical study no pre-existing lenacapavir resistance was detected. Emergence of Q67H occurred at exposures below the dose used in current Phase 2/3 studies. These results support development of lenacapavir as an antiretroviral agent.

Me gusta

Guardar

Cite This Study

Margot et al. (Tue,) studied this question.

synapsesocial.com/papers/69d879488c03fbaff8bef34e https://doi.org/https://doi.org/10.1093/jac/dkab503

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes2020 · 63 citations
2Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults2017 · 100 citations
3Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results2013 · 117 citations
4A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors1997 · 80 citations
5A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 12000 · 653 citations

Me gusta

Guardar